Self-Deleting Lentiviral Vector Service
After almost 30 years of development, gene therapies are rapidly becoming a critical component of the therapeutic armamentarium for a variety of inherited and acquired human diseases. Lentiviral vector is widely used as an effective transduction tool in gene therapy. Creative Biolabs has been occupied in the research of gene therapy for more than ten years. We focus on the field of inherited human diseases research with a professional lentiviral vector design platform that can help you with gene therapy development. We can provide comprehensive technologies to meet the diverse requirements of our clients.
Introduction of Self-Deleting Lentiviral Vector
Self-deleting lentiviral vectors have been developed on the basis of the Cre/loxP system. The site-specific recombinase of the bacteriophage P1, Cre, catalyzes the recombination of two 34-bp sequences called the loxPs, which consist of two 13-bp palindromic sequences flanking an 8-bp core sequence. Cre/loxP system is a site-specific recombinase technology for deletions, insertions, translocations and inversions at specific sites in cellular DNA. It allows DNA modification to be localized to specific cell types or triggered by a specific external stimulus. Self-deletion is achieved by expression of the Cre recombinase from vectors with a loxP site into the U3 region of the 3'-LTR. Duplication of the U3 region of the 3'-LTR during reverse transcription generates a proviral DNA with one loxP site in both LTRs. After integration and subsequent Cre expression, Cre-mediated recombination of these two loxP sites deletes most of the integrated vector genome with the exception of the flanking U sequences and one loxP site. Because of the high efficiency of the Cre/loxP system in mammalian cells, this system is now widely used for gene therapy.
Figure 1. Self-deleting lentiviral vector service.
The Service of Self-Deleting Lentiviral Vector
The Cre lentiviral vectors effectively transferred Cre to the target cells and induced Cre-mediated recombination of loxP sites in a variety of target cells, including neurons, hepatocytes, and hematopoietic progenitors. Serval studies have demonstrated that by incorporation of Cre and loxP into one single lentiviral vector, one can achieve transient expression of Cre in vivo.
The design of lentiviral vector demands both in-depth expertise and flexible execution. Creative Biolabs is the right partner to assist you in bringing new gene therapy approaches to the market. We have focused on the development of gene therapies for years. If you are interested in our services, please feel free to contact us and our experienced technicians will give you the most detailed answers to your questions.
